Peter R. Galle

108.5k total citations · 28 hit papers
1.2k papers, 55.7k citations indexed

About

Peter R. Galle is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Peter R. Galle has authored 1.2k papers receiving a total of 55.7k indexed citations (citations by other indexed papers that have themselves been cited), including 377 papers in Hepatology, 330 papers in Epidemiology and 290 papers in Oncology. Recurrent topics in Peter R. Galle's work include Liver Disease Diagnosis and Treatment (206 papers), Hepatocellular Carcinoma Treatment and Prognosis (180 papers) and Liver Disease and Transplantation (105 papers). Peter R. Galle is often cited by papers focused on Liver Disease Diagnosis and Treatment (206 papers), Hepatocellular Carcinoma Treatment and Prognosis (180 papers) and Liver Disease and Transplantation (105 papers). Peter R. Galle collaborates with scholars based in Germany, United States and France. Peter R. Galle's co-authors include Markus F. Neurath, Vincenzo Mazzaferro, Josep M. Llovet, Alejandro Forner, Jean‐Luc Raoul, Peter Schirmacher, Fabio Piscaglia, Valérie Vilgrain, Ralf Kießlich and Wolfgang Stremmel and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Peter R. Galle

1.2k papers receiving 54.5k citations

Hit Papers

EASL Clinical Practice Gu... 1995 2026 2005 2015 2018 2021 2008 2014 2004 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
    2018 6.9k citations Peter R. Galle, Josep M. Llovet et al. Journal of Hepatology profile →
  2. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
    2021 2.3k citations Peter R. Galle, Amit G. Singal et al. Journal of Hepatology profile →
  3. Simplified criteria for the diagnosis of autoimmune hepatitis†
    2008 1.2k citations Peter R. Galle, Ansgar W. Lohse et al. Hepatology profile →
  4. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
    2014 1.0k citations Peter R. Galle, Josep M. Llovet et al. Journal of Hepatology profile →
  5. Cutting Edge: TGF-β Induces a Regulatory Phenotype in CD4+CD25− T Cells through Foxp3 Induction and Down-Regulation of Smad7
    2004 928 citations Peter R. Galle, Markus F. Neurath et al. profile →
  6. Colorectal cancer
    2005 922 citations Peter R. Galle et al. profile →
  7. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
    2021 891 citations Ann‐Lii Cheng, Shukui Qin et al. Journal of Hepatology profile →
  8. Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?
    1996 775 citations Dennis Strand, Peter H. Krammer et al. profile →
  9. p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
    1998 704 citations Peter R. Galle, Peter H. Krammer et al. profile →
  10. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
    2012 656 citations Peter R. Galle, Josep M. Llovet et al. Journal of Hepatology profile →
  11. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.
    1997 653 citations Peter H. Krammer, Peter R. Galle et al. profile →
  12. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes
    2003 634 citations Dennis Strand, Hans A. Lehr et al. profile →
  13. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo
    2004 609 citations Ralf Kießlich, Peter R. Galle et al. profile →
  14. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis
    2003 606 citations Ralf Kießlich, Martin Holtmann et al. profile →
  15. TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling
    2004 590 citations Hans A. Lehr, Stefan Wirtz et al. profile →
  16. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.
    1995 586 citations Peter R. Galle, Peter H. Krammer et al. profile →
  17. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
    1995 576 citations Peter R. Galle et al. profile →
  18. The Transcription Factor T-bet Regulates Mucosal T Cell Activation in Experimental Colitis and Crohn's Disease
    2002 502 citations Markus F. Neurath, Susetta Finotto et al. profile →
  19. Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions
    2013 492 citations Peter R. Galle et al. profile →
  20. Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma
    2019 409 citations Peter R. Galle, Masatoshi Kudo et al. profile →
  21. Systemic treatment of hepatocellular carcinoma: An EASL position paper
    2021 243 citations Peter R. Galle et al. Journal of Hepatology profile →
  22. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
    2020 240 citations Josep M. Llovet, Augusto Villanueva et al. Hepatology profile →
  23. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
    2021 229 citations Richard S. Finn, Masafumi Ikeda et al. profile →
  24. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options
    2021 183 citations Peter R. Galle et al. Journal of Hepatology profile →
  25. Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population
    2021 171 citations Peter R. Galle, Pere Ginès et al. profile →
  26. Emerging immunotherapy for HCC: A guide for hepatologists
    2022 158 citations Peter R. Galle et al. Hepatology profile →
  27. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
    2024 145 citations Peter R. Galle et al. Journal of Hepatology profile →
  28. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
    2024 75 citations Peter R. Galle, Masatoshi Kudo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter R. Galle Germany 102 19.4k 16.1k 13.4k 11.4k 11.0k 1.2k 55.7k
Masao Omata Japan 112 19.5k 1.0× 17.7k 1.1× 8.9k 0.7× 10.0k 0.9× 13.6k 1.2× 1.1k 50.7k
Gregory J. Gores United States 142 19.0k 1.0× 20.1k 1.2× 14.2k 1.1× 19.3k 1.7× 23.6k 2.1× 591 63.2k
Joseph J.�Y. Sung Hong Kong 140 10.6k 0.5× 21.5k 1.3× 13.6k 1.0× 23.3k 2.0× 23.4k 2.1× 1.3k 86.8k
David A. Brenner United States 132 22.0k 1.1× 26.8k 1.7× 5.0k 0.4× 20.1k 1.8× 9.0k 0.8× 517 59.5k
Scott L. Friedman United States 119 30.7k 1.6× 32.5k 2.0× 6.1k 0.5× 18.1k 1.6× 9.6k 0.9× 438 61.8k
Peter Schirmacher Germany 86 10.6k 0.5× 9.2k 0.6× 11.6k 0.9× 10.9k 1.0× 6.8k 0.6× 681 36.7k
Hashem B. El‐Serag United States 123 26.2k 1.4× 28.1k 1.7× 10.2k 0.8× 12.2k 1.1× 23.3k 2.1× 654 69.4k
Kazuaki Chayama Japan 99 14.9k 0.8× 15.7k 1.0× 7.4k 0.6× 7.5k 0.7× 10.7k 1.0× 1.4k 45.3k
Masatoshi Kudo Japan 103 30.9k 1.6× 17.6k 1.1× 13.1k 1.0× 5.5k 0.5× 11.0k 1.0× 1.4k 48.7k
David E. Kleiner United States 100 17.6k 0.9× 32.1k 2.0× 6.8k 0.5× 8.0k 0.7× 7.3k 0.7× 515 50.7k

Countries citing papers authored by Peter R. Galle

Since Specialization
Citations

This map shows the geographic impact of Peter R. Galle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter R. Galle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter R. Galle more than expected).

Fields of papers citing papers by Peter R. Galle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter R. Galle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter R. Galle. The network helps show where Peter R. Galle may publish in the future.

Co-authorship network of co-authors of Peter R. Galle

This figure shows the co-authorship network connecting the top 25 collaborators of Peter R. Galle. A scholar is included among the top collaborators of Peter R. Galle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter R. Galle. Peter R. Galle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Angeli, Paolo, Christian Labenz, Salvatore Piano, et al.. (2025). Albumin infusion in hepatorenal syndrome-acute kidney injury: New evidence challenges recent consensus. Journal of Hepatology. 83(3). 800–802. 3 indexed citations
2.
3.
4.
Llovet, Josep M., Amit G. Singal, Augusto Villanueva, et al.. (2022). Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clinical Cancer Research. 28(11). 2297–2305. 13 indexed citations
5.
Hahad, Omar, Manfred E. Beutel, Donya Gilan, et al.. (2022). Noise annoyance and risk of prevalent and incident atrial fibrillation–A sex-specific analysis. Frontiers in Public Health. 10. 1061328–1061328. 11 indexed citations
6.
Labenz, Christian, Gerrit Toenges, Yvonne Huber, et al.. (2019). Raised serum Interleukin‐6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy. Alimentary Pharmacology & Therapeutics. 50(10). 1112–1119. 38 indexed citations
7.
Zimmermann, Tim, D. Hueppe, Stefan Mauss, et al.. (2016). Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1. Journal of Gastrointestinal and Liver Diseases. 25(1). 15–24. 4 indexed citations
8.
Maderer, Annett, et al.. (2014). Moguntinones—New Selective Inhibitors for the Treatment of Human Colorectal Cancer. Molecular Cancer Therapeutics. 13(6). 1399–1409. 6 indexed citations
9.
Weber, Achim, Regina Boger, Binje Vick, et al.. (2009). Hepatocyte‐specific deletion of the antiapoptotic protein myeloid cell leukemia‐1 triggers proliferation and hepatocarcinogenesis in mice†. Hepatology. 51(4). 1226–1236. 95 indexed citations
10.
Staib, Frank, Ana I. Robles, Lyuba Varticovski, et al.. (2005). The p53 Tumor Suppressor Network Is a Key Responder to Microenvironmental Components of Chronic Inflammatory Stress. Cancer Research. 65(22). 10255–10264. 87 indexed citations
11.
Denzer, U, Sebastian Hoffmann, I Helmreich-Becker, et al.. (2004). Minilaparoscopy in the diagnosis of peritoneal tumor spread: prospective controlled comparison with computed tomography. Surgical Endoscopy. 18(7). 1067–1070. 32 indexed citations
12.
Relle, Manfred, et al.. (2003). Proteinase 3/myeloblastin as a growth factor in human kidney cells. Journal of Nephrology. 16(6). 831–840. 5 indexed citations
13.
Denzer, U, Klaus Mergener, S Kanzler, et al.. (2003). Mini-Laparoscopically Guided Percutaneous Gastrostomy and Jejunostomy. Gastrointestinal Endoscopy. 58(3). 434–438. 16 indexed citations
14.
Galle, Peter R., et al.. (2003). Metrological data and risk assessment in France during the Chernobyl accident. Historical statement. Comptes Rendus Biologies. 699–715. 1 indexed citations
15.
Finotto, Susetta, Markus F. Neurath, Jonathan N. Glickman, et al.. (2002). Development of Spontaneous Airway Changes Consistent with Human Asthma in Mice Lacking T-bet. Science. 295(5553). 336–338. 490 indexed citations
16.
Nieuwenhuis, Edward E. S., Markus F. Neurath, Nadia Corazza, et al.. (2002). Disruption of T helper 2-immune responses in Epstein–Barr virus-induced gene 3-deficient mice. Proceedings of the National Academy of Sciences. 99(26). 16951–16956. 151 indexed citations
17.
Galle, Peter R., et al.. (2001). Quantitative analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in interferon‐α‐treated patients with chronic hepatitis C. Journal of Medical Virology. 64(3). 340–349. 23 indexed citations
18.
Holtmann, Martin, Peter R. Galle, & Markus F. Neurath. (2001). Immunotherapeutic approaches to inflammatory bowel diseases. Expert Opinion on Biological Therapy. 1(3). 455–466. 10 indexed citations
19.
Rahman, Fareed, Anja Dahmen, Sabine Herzog‐Hauff, et al.. (2000). Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology. 31(2). 521–527. 132 indexed citations
20.
Galle, Peter R., et al.. (1992). Role of alveolar macrophages in precipitation of mineral elements inhaled as soluble aerosols.. Environmental Health Perspectives. 97. 145–147. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masao Omata Breakdown of academic impact, for papers by Gregory J. Gores Breakdown of academic impact, for papers by Joseph J.�Y. Sung Breakdown of academic impact, for papers by David A. Brenner Breakdown of academic impact, for papers by Scott L. Friedman Breakdown of academic impact, for papers by Peter Schirmacher Breakdown of academic impact, for papers by Hashem B. El‐Serag Breakdown of academic impact, for papers by Kazuaki Chayama Breakdown of academic impact, for papers by Masatoshi Kudo Breakdown of academic impact, for papers by David E. Kleiner
Rankless by CCL
2026